Genix Pharmaceuticals Corporation (TSE:GENX) has released an update.
Genix Pharmaceuticals Corporation has received TSX Venture Exchange approval for amendments to their warrants, including a reduction in exercise price from $0.30 to $0.15 per share and an extension of the expiry dates to July and August 2025. The company has corrected the total number of warrants from previous releases and issued an apology for any confusion caused by past clerical errors. Genix is a company specializing in novel and generic ophthalmic drugs, focusing on the development and sale of proprietary healthcare products.
For further insights into TSE:GENX stock, check out TipRanks’ Stock Analysis page.
